NMRANeumora Therapeutics Inc.
$1.61
$0.08
(4.71%)
Closed $1.62
$0.01
(0.62%)
After Hours
EarningsAug 6
Mkt Cap$314.98M
Vol960,690.00
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who...
Business Wire
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations PR Newswire NEW YORK, June 17, 2026 Neumora Therapeutics...
PR Newswire
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) PR Newswire NEW YORK, June 16...
PR Newswire
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
Zacks
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday
Neumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-neumora-therapeutics-inc-stock...
MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports...
MarketBeat
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...
MarketBeat
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)
Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...
MarketBeat
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest NMRA News
ViewNMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
Business Wire
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations
PR Newswire
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
PR Newswire
Advertisement|Remove ads.